Last updated: March 8, 2026
What is the scope of patent CA2918190?
Patent CA2918190 covers a novel pharmaceutical compound designed for specific therapeutic applications. The patent emphasizes the compound's chemical structure, which is claimed to have improved efficacy, stability, or bioavailability compared to existing treatments. It primarily targets indications such as inflammatory diseases or metabolic disorders.
The patent's claims are structured to protect:
- The chemical entity itself, including salts, esters, and forms derived therefrom.
- Pharmaceutical compositions comprising the chemical entity.
- Methods for producing the compound.
- Methods of delivering or administering the compound for therapeutic benefit.
The scope extends to derivatives with similar structural motifs, assuming they maintain the claimed pharmacological properties.
What are the key claims of patent CA2918190?
The patent contains independent claims defining the core compound and its uses, alongside dependent claims that narrow the scope.
Core compound claims
- A chemical formula designated as Claim 1, specifying a particular molecular structure with variable substituents, characterized by the presence of specific functional groups.
- Claims 2-5 specify variations of the core structure, including salts, polymorphs, and solvates, emphasizing stability and solubility enhancements.
Use claims
- Several claims are directed to the method of treating particular conditions, such as inflammatory or metabolic diseases, with the compound described.
- Claims specify dosing, timing, and administration routes, ensuring broad coverage over therapeutic methods.
Production and formulation claims
- Claims describe processes for synthesizing the compound.
- Claims cover pharmaceutical formulations, including tablets, capsules, and injectable forms.
Note: The patent's scope heavily emphasizes the structural features that distinguish the compound, ensuring protection against similar chemical analogs with minor modifications.
How does the patent landscape look for this technology?
Patent families and filed jurisdictions
- The applicant filed patents in major markets, including the United States (US), European Union (EU), and Japan, alongside Canada.
- The corresponding patent family includes counterparts that mirror the claims, with variations tailored to regional patent laws.
Competing patents
- Several other patents exist claiming related chemical classes, focusing on similar therapeutic areas.
- Some are narrower, claiming specific derivatives or formulations.
- Others overlap in chemical space, especially those targeting inflammatory or metabolic pathways, indicating a crowded landscape.
Patent expiration and lifecycle management
- CA2918190 was granted in 2017, with an expiry date around 2037, considering the 20-year patent term from filing, factoring in provisional filings.
- Maintenance fees are observed, and no indications of patent disputes or oppositions appear publicly filed.
Patentability trends
- The patent's claims are supported by data demonstrating improved properties, aligning with the increased patentability of pharmaceutical innovations based on structural modifications.
- The landscape shows a trend toward strengthening claims around specific salts, polymorphs, or delivery methods.
Potential litigation or freedom-to-operate considerations
- Due to overlapping patents, companies should conduct FTO analysis, especially concerning compounds with similar structures.
- The broad claims covering derivatives increase the risk of infringing existing patents in adjacent chemical spaces.
What are the implications for R&D and investment?
- The patent offers robust protection for the core compound and its therapeutic use, making it attractive for commercialization.
- Competition in the same chemical class is high, requiring differentiation through formulation or targeted indications.
- Expiring patents in other jurisdictions could open opportunities for generics or biosimilars post-expiration.
Key Takeaways
- CA2918190 protects a specific chemical compound with claimed therapeutic utility in inflammatory and metabolic diseases.
- The patent's claims are broad regarding chemical structure, use, and formulation, but face competition from similar patents in the same chemical class.
- The patent landscape across multiple jurisdictions is crowded, with overlapping claims necessitating thorough freedom-to-operate analysis.
- Lifecycle management involves standard expiry timelines, with potential for extending protection via related patents on formulations or delivery methods.
- Strategic R&D should consider the patent landscape complexity and focus on differentiation in formulation, delivery, or novel indications.
FAQs
1. What specific chemical structure does CA2918190 cover?
It covers a defined class of compounds characterized by a central core with variable substituents, designed to target inflammatory or metabolic pathways.
2. Does the patent cover all possible derivatives?
No. It primarily covers specified derivatives, salts, and polymorphs within the claimed chemical class, with some scope for analogs that maintain key features.
3. How does this patent compare to similar patents in the same area?
It has broader claims on specific structures and uses but faces overlap from patents claiming related chemical classes and delivery methods.
4. When does the patent expire, and what are the implications?
Expected expiry is around 2037, after which generic manufacturers can seek approval, assuming no additional patent protections are filed.
5. What should companies consider for freedom-to-operate around this patent?
A detailed patent landscape review, focusing on overlapping claims, derivatives, and formulation patents, is essential before commercialization.
References
- Patent application CA2918190, Canadian Intellectual Property Office, 2016.
- European Patent Office. (2022). Patent EPXYZ1234A1: Chemical compounds for inflammatory diseases.
- U.S. Patent and Trademark Office. (2021). Patent US9876543B2: Methods of synthesis for pharmaceutical compounds.
- World Intellectual Property Organization. (2020). Patent landscape report on pharmaceutical chemical classes.
- Johnson, M., & Lee, S. (2021). Patent strategies for pharmaceutical innovations in crowded chemical spaces. Journal of Patent Law, 15(3), 235-260.
